Comanche Biopharma

Comanche Biopharma is a clinical-stage biopharmaceutical company dedicated to developing the world's first treatment for preeclampsia, a serious and prevalent pregnancy complication that affects over 10 million women annually. The company's mission is to eradicate preeclampsia globally and ensure access to their solutions for those who need them most. They are harnessing the power of siRNA technology, which instructs the body's natural mechanisms to reduce the production of a protein called sFlt1, a key driver of preeclampsia.

Comanche Biopharma has assembled a team of experienced physicians, researchers, biologists, chemists, ethicists, and pharmaceutical professionals, as well as a diverse Board of Directors. They have received significant funding from top-tier investors, including New Enterprise Associates and Atlas Venture, validating their innovative science, clinical progress, and experienced team. Their lead siRNA drug candidate, CBP-4888, is currently in clinical trials, aiming to ameliorate maternal symptoms, avoid premature delivery, and improve maternal and neonatal outcomes.

Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company focused on developing the first definitive treatment for sFlt1-mediated preterm preeclampsia and making it globally available. Their mission is to eradicate preeclampsia worldwide by providing safe and effective therapies that are evidence-based and affordable, ensuring that all women and their babies have access to the treatment they need.

Comanche Biopharma fosters a culture that prioritizes innovation and collaboration, driven by a shared passion for improving maternal health globally. The company values ethical representation, prioritizing access to its solutions for those most in need. They recognize the importance of patient advocacy and integrate the patient experience into every facet of their business, demonstrating a deep commitment to improving the lives of individuals affected by preeclampsia.

Comanche Biopharma is committed to fostering a diverse and inclusive workplace and ensuring ethical representation of people of all colors and economic status globally in their clinical development programs. They prioritize ensuring access to their solutions by those who need them most, recognizing that preeclampsia disproportionately affects women of color and those in lower socioeconomic status.